Beetroot juice for people with high blood pressure and kidney damage
Tests dietary nitrate, given as beetroot juice, in adults with hypertension and kidney injury.
Plain-language title generated from the registry record
Registry title: The Effects of Dietary Nitrate in Patients With Hypertensive Kidney Injury
Key facts
- Where
- Herning, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07290842, who can take part
Where in Denmark
- University Clinic in Nephrology and Hypertension, Gødstrup Regional Hospital and Aarhus UniversityHerning, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gødstrup Hospital
- Trial code
- NCT07290842
- Record updated
- 18 December 2025
- Original description
The study aims to study the effects of diatery nitrate in patients with hypertension and hypertensive kidney injury.Read full original descriptionShow less
The Effects of Dietary Nitrate in Patients With Hypertensive Kidney Injury
The study aims to study the effects of diatery nitrate in patients with hypertension and hypertensive kidney injury.
The study is a randomized, placebo-controlled, double-blinded crossover trial. 14-20 patients with hypertension and CKD I-III will be randomized to receive either nitrate or placebo delivered in the form of beetroot juice.
Effect variables will be measured before and after a 2 week treatment. After a washout period of 14 days, the subjects are crossed over to the opposite treatment.
The study is terminated by measuring effect variables after the second treatment period.
Inclusion: Hypertension, treated with a maximum of 2 antihypertensive drugs and unattended office BP < 150/95 mmHg at the screening visit, or newly diagnosed without antihypertensive treatment by 24-hour BP or home BP measurement (above 130/80 or 135/85 respectively), and unattended office BP < 160/100 mmHg; CKD I-III based on hypertensive kidney injury. Patients, who previously met the criteria for CKD I within the last 5 years, but no longer has proteinuria after relevant treatment, can also be included. Diagnosis of CKD I can be based on eGFR and either urine albumin/creatine ration or urine-dipstick test with presence of protein; Albumin/creatinine ratio < 500 mg/g; eGFR > 30 ml/min/1,73m2; Body Mass Index (BMI) ≤ 35 kg/m2; Able to adhere to dietary regimen; Fertile women must use safe contraception (oral contraceptive pill, hormonal or copper intrauterine device, vaginal ring, contraceptive implant, transdermal contraceptive patch or contraceptive injections) or abstinence. Excluded from this are postmenopausal woman without menstrual bleeding for at least 12 months before inclusion, surgically sterilized women and women with surgically sterilized partner.
Exclusion: • Diagnosis of heart failure, NYHA II-IV; Diagnosis of liver failure; Diabetes mellitus (all types); Current malignant disease (other than non-melanoma skin cancer); Indicators of other aetiologies of CKD than hypertensive kidney injury, e.g. through kidney biopsy or biochemistry; Previous kidney transplant recipient; History of stroke or transient cerebral ischemic attack; Current indication of untreated cardiovascular disease, e.g. planned work-up for ischemia; History of myocardial infarction, apart from non-STEMI more than 1 year prior to the study, if the subject is currently revascularized and relevantly medicated; Organic nitrate treatment Diagnosed secondary hypertension other than renal parenchymal hypertension (i.e. renal artery stenosis, primary hyperaldosteronism, low renin hypertension etc.); Conditions treated with medication that investigator finds may interfere with the effect parameters, and cannot be discontinued during the trial (e.g. atrial fibrillation treated with betablockers); Pregnancy or lactation; Alcohol abuse (intake above the recommended guidelines from Danish Health Authorities); If, according to the investigator's assessment, the participant is considered unsuitable to participate.